Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Insulin-Like-Growth Factor I Receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti-IGF-I receptor antibody
InactiveUS20050249728A1Increase profitOrganic active ingredientsFungiSynovial sarcomaAbnormal tissue growth
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
Owner:IMMUNOGEN INC
Antibodies against insulin-like growth factor 1 receptor and uses thereof
ActiveUS20050008642A1Slow tumor growthExtension of timeImmunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsBiologyAntibody
Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
Owner:F HOFFMANN LA ROCHE & CO AG
Antibodies to insulin-like growth factor I receptor
Owner:AMGEN FREMONT INC +1
Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
InactiveUS20130084243A1High affinityUseful in detectionAnimal cellsIn-vivo radioactive preparationsDiseaseSingle-Chain Antibodies
The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.
Owner:GOETSCH LILIANE +4
Anti-IGF-I receptor antibody
InactiveUS7538195B2Increase profitOrganic active ingredientsFungiInsulin-like growth factorSynovial sarcoma
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
Owner:IMMUNOGEN INC
IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
InactiveUS8344112B2Useful in detectionConveniently assayedBiological material analysisAntibody ingredientsDiseaseSingle-Chain Antibodies
The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGF-1R.
Owner:MERCK SHARP & DOHME CORP +1
Antibodies to insulin-like growth factor I receptor
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and / or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
Owner:AMGEN FREMONT INC +1
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
ActiveUS20100121033A1Reduce activationDistribution morePeptide/protein ingredientsAntibody mimetics/scaffoldsNucleotidePolynucleotide
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Owner:BRISTOL MYERS SQUIBB CO
Stable antibody formulations
InactiveUS20100260766A1Pharmaceutical delivery mechanismAntibody ingredientsInsulin-like growth factorAntibody
The present invention provides formulations and methods for the stabilization of antibodies. In one embodiment, the invention provides the stable solution formulation of an IgG1 antibody that specifically binds to insulin-like growth factor-I receptor. In another embodiment, the invention provides methods of stabilization of IgG1 antibody that specifically binds to insulin-like growth factor-I receptor comprising lyophilizing an aqueous formulation of the antibody. The formulations can be lyophilized to stabilize the antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration.
Owner:IMCLONE SYSTEMS
Antibodies against insulin-like growth factor I receptor and uses thereof
InactiveUS20080226635A1Enhanced effector functionEvade inhibitory effectAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsSugarAntibody
Owner:F HOFFMANN LA ROCHE INC
Antibodies against insulin-like growth factor I receptor and uses thereof
InactiveUS20080014203A1Prolongates time to progressionSlow tumor growthAnimal cellsImmunoglobulins against growth factorsLactoseSugar
An antibody binding to IGF-IR, being of human IgG1 or IgG3 type and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 98%, and in addition the amount of NGNA is 1% or less and / or the amount of N-terminal alpha-1,3-galactose is 1% or less has improved properties in antitumor therapy.
Owner:F HOFFMANN LA ROCHE & CO AG
Modulation of insulin like growth factor i receptor expression
InactiveUS20060234239A1Modulate expressionOrganic active ingredientsBiocideGrowth Factor GeneInflammatory dermatosis
The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.
Owner:ANTISENSE THERAPEUTICS LTD
Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
InactiveUS20100215573A1High affinityUseful in detectionAnimal cellsIn-vivo radioactive preparationsDiseaseSingle-Chain Antibodies
The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.
Owner:MERCK SHARP & DOHME CORP +1
Nonapoptotic forms of cell death and methods of modulation
The invention is directed to methods for identifying molecules that modulate paraptosis, a newly identified nonapoptotic form of programmed cell death. The invention also provides a method of inhibiting paraptosis by preventing association of caspase-9 and an endogenous paraptosis-mediating molecule. In one embodiment, the invention provides a method of inhibiting paraptosis by preventing association of caspase-9 and the Insulin-Like Growth Factor I Receptor (IGFIR). The invention further is directed to therapeutic methods for treatment of pathologies associated with aberrant levels of paraptosis such as neural cell death disorders and neoplastic disorders. Also provided by the present invention are methods of identifying endogenous paraptosis-mediating molecules.
Owner:THE BURNHAM INST +1
Anti-IGF-IR antibodies and uses thereof
ActiveUS8361461B2Increased serum half-lifeInhibit growthImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseTherapeutic treatment
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and / or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and / or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and / or the IGF-I / Insulin hybrid receptor.
Owner:PIERRE FABRE MEDICAMENT SAS
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
InactiveCN101636410AImprove stabilityImprove solubilityConnective tissue peptidesTransferasesNucleotideADAMTS Proteins
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Owner:BRISTOL MYERS SQUIBB CO
Pharmaceutical composition containing insulin-like growth factor-I receptor inhibitor and histon deacetylase (HDAC) inhibitor and application thereof
InactiveCN101757626AGood synergyGood curative effectOrganic active ingredientsAntineoplastic agentsInsulin-like growth factorSide effect
The invention relates to a pharmaceutical composition containing an insulin-like growth factor-I receptor inhibitor and a histon deacetylase (HDAC) inhibitor and an application thereof in preparing medicines for treating intestinal cancer, liver cancer, lung cancer, kidney cancer, gastric cancer, brain tumor, sarcoma, pancreatic cancer, ovarian cancer, breast cancer or prostate cancer. The pharmaceutical composition of the invention has obvious synergistic effect, thus improving curative effect of medicines, lowering administration dosage and reducing occurrence of side effect.
Owner:DINKUM INT INVESTMENT HONG KONG
Modulation of insulin like growth factor i receptor expression in cancer
InactiveUS20100093832A1Inhibit expressionReduce transcriptionOrganic active ingredientsFermentationWilms' tumorInsulin-Like-Growth Factor I Receptor
Provided herein are methods, compounds, and compositions for reducing expression of an IGF-IR mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions that inhibit expression of IGF-IR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate the tumor or cancer, or a symptom thereof.
Owner:ANTISENSE THERAPEUTICS LTD
Anti-IGF-I receptor antibody
InactiveCN1886424AGrowth inhibitionSugar derivativesImmunoglobulins against cell receptors/antigens/surface-determinantsSynovial sarcomaAntibody fragments
Antibodies, humanized antibodies, resurfaced antibodies antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. The antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer and the derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
Owner:IMMUNOGEN INC
Method for inducing retinal stem cells to differentiate into photosensory cells
InactiveCN102618490ANo confoundingHigh differentiation efficiencyVertebrate cellsArtificial cell constructsVirus typeMature cell
The invention discloses a method for inducing retinal stem cells to differentiate into photosensory cells, which includes inhibiting IGF IR alpha (insulin-like growth factor I receptor alpha) of a retinal stem cell so as to lead the retinal stem cell to differentiate into photosensory cells. Compared with the prior art, the method introduces no virus gene and needs no genetic manipulation, cross contamination of retinal mature cells is avoided, and the method is high in differentiation efficiency and simple to operate.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Rockfish insulin like growth factor I receptor gene and its application
InactiveCN1597954ASignificant economic valuePromote growthInsulin-like growth factorsGenetic engineeringInsulin-like growth factorTotal rna
The invention discloses a rockfish insulin-like growth factor I receptor gene, which is a gene fragment with rockfish insulin-like growth factor I receptor gene cDNA sequence, obtained by using rockfish hypothalamic total RNA as a template and by RT-PCR and Gene RACER methods. The invention can obtain stable-source and low-cost recombinant protein of rockfish insulin-like growth factor I receptor, having an important application to preparing fry growth promoter or additive.
Owner:SUN YAT SEN UNIV
Modulation of insulin like growth factor I receptor expression
The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.
Owner:ANTISENSE THERAPEUTICS LTD
Antibodies Against Insulin-Like Growth Factor I Receptor and Uses Thereof
InactiveUS20120076778A1Slow tumor growthExtension of timeAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsWilms' tumorAntibody
Owner:KOLL HANS +3
Modulation of insulin like growth factor i receptor expression
InactiveUS20090111767A1Modulate expressionOrganic active ingredientsSugar derivativesGrowth Factor GeneFactor ii
The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.
Owner:ANTISENSE THERAPEUTICS LTD
Insulin-like growth factor-i receptor antagonists
InactiveUS20090311783A1Inhibit cell proliferationPeptide/protein ingredientsPeptide preparation methodsApoptosisSignal transduction
The present invention relates to IGF-I variants that bind to the Insulin-like Growth Factor Receptor I (IGF-IR) but do not initiate signal transduction and the subsequent metabolic, growth and anti-apoptotic activities associated with this molecule and the progression of cancer. These novel variants act to block the binding of the cognate ligands but do not bind to the insulin receptor.
Owner:MOLECULAR LOGIX INC
Antibodies against insulin-like growth factor i receptor and uses thereof
ActiveUS20080132686A1Extension of timeSlow tumor growthImmunoglobulins against growth factorsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibodyInsulin-Like-Growth Factor I Receptor
Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
Owner:F HOFFMANN LA ROCHE & CO AG
Modulation of Insulin Like Growth Factor I Receptor Expression in Cancer
Provided herein are methods, compounds, and compositions for reducing expression of an IGF-IR mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions that inhibit expression of IGF-IR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate the tumor or cancer, or a symptom thereof.
Owner:ANTISENSE THERAPEUTICS LTD
Anti-igf-i receptor antibodies
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
Owner:IMMUNOGEN INC
Kit and application method for combined detection of duck igf-I and igf-IR gene mrna expression
InactiveCN103497886BUnique designLow priceBioreactor/fermenter combinationsBiological substance pretreatmentsReference genesInsulin-like growth factor
The invention discloses a kit for joint detection on mRNA (messenger Ribose Nucleic Acid) expression quantity of IGF-I (Insulin-like Growth Factor) and IGF-IR (Insulin-like Growth Factor I Receptor) genes of ducks and a using method of the kit. The kit comprises a kit body (1), an isolating pad (2), an IGF-I gene mosaic specific upstream and downstream primer (3), an IGF-IR gene mosaic specific upstream and downstream primer (4), a reference gene ACTB (actin beta) gene mosaic specific upstream and downstream primer (5), an IGF-I gene internal control DNA (6), an IGF-IR gene internal control DNA (7) and a Tag enzyme DNA ligase (8). The kit, which is special in design and is stable and efficient, is combined with an MCF-PCR (Malignant Catarrhal Fever-Polymerase Chain Reaction) technology, and thus a detection method is reliable and convenient and is low in price.
Owner:朱文奇
Method for inducing retinal stem cells to differentiate into photosensory cells
InactiveCN102618490BNo confoundingHigh differentiation efficiencyArtificial cell constructsVertebrate cellsMature cellGenetics manipulation
The invention discloses a method for inducing retinal stem cells to differentiate into photosensory cells, which includes inhibiting IGF IR alpha (insulin-like growth factor I receptor alpha) of a retinal stem cell so as to lead the retinal stem cell to differentiate into photosensory cells. Compared with the prior art, the method introduces no virus gene and needs no genetic manipulation, cross contamination of retinal mature cells is avoided, and the method is high in differentiation efficiency and simple to operate.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com